Hansa Biopharma

Hansa Biopharma AB (publ), a biopharmaceutical company, develops immunomodulatory treatments for enabling transplants and rare immunoglobulin G (IgG)-mediated autoimmune conditions, gene therapy, and cancer using its proprietary enzyme technology platform. The company's lead drug candidate is Imlifidase, an antibody cleaving enzyme therapy that is in phase 3 clinical trial for use in sensitized kidney transplantations patients, as well as for anti-GBM antibody disease; and phase 2 clinical trial for antibody-mediated kidney transplant rejection and Guillain Barré syndrome. It is also developing Novel immunoglobulin cleaving enzymes for Repeat dosing (NiceR) for the treatment of autoimmune diseases, transplantation, and oncology; and Enzyme based antibody Enhancement (EnzE), which is cancer immunotherapy. The company has a preclinical research collaboration agreement with argenx BV to evaluate the therapeutic potential of combining the two companies' IgG-modulating technologies. Hansa Biopharma AB (publ) was incorporated in 2007 and is headquartered in Lund, Sweden.

We are devoted to developing innovative, evidence-based therapies to improve and extend the lives of those affected by severe autoimmune diseases.

We strive to become the global leader in immunomodulatory enzyme technology and the preferred partner for developing, producing and commercializing novel biologicals for the treatment of autoimmune diseases.

In 2017, Hansa Biopharma won the Sweden Bio's Deal of the Year Award for its collaboration with Takeda to develop and commercialize its novel enzyme therapeutic.